vTv Therapeutics (VTVT) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChart

VTVT Stock Forecast


vTv Therapeutics stock forecast is as follows: a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

VTVT Analyst Ratings


Buy

According to 1 Wall Street analysts, vTv Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for VTVT stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Feb 18, 2022Cantor Fitzgerald-OverweightInitialise
Row per page
Go to

vTv Therapeutics's last stock rating was published by Cantor Fitzgerald on Feb 18, 2022. The company Initialise its VTVT rating from "null" to "Overweight".

vTv Therapeutics Financial Forecast


vTv Therapeutics Revenue Forecast

Dec 24Sep 24Jun 24Dec 22Sep 22Dec 21Sep 21Jun 21Mar 21Dec 20Jun 20Dec 19Sep 19Jun 19Mar 18Mar 17Mar 16Sep 15
Revenue---$9.00K-$4.00K$3.00M$9.00K$987.00K$6.40M-$7.00K$8.00K$1.83M$2.06M$30.00K$376.00K$133.00K
Avg Forecast---$3.09M$250.00K$500.00K$1.30M$1.00M$800.00K$3.30M$10.29K$1.25M$1.69M$1.63M$2.34M$30.00K$859.43K$317.57K
High Forecast---$3.70M$250.00K$500.00K$1.30M$1.00M$800.00K$3.30M$12.34K$1.25M$1.69M$1.63M$2.81M$36.00K$1.03M$381.08K
Low Forecast---$2.47M$250.00K$500.00K$1.30M$1.00M$800.00K$3.30M$8.23K$1.25M$1.69M$1.63M$1.87M$24.00K$687.54K$254.06K
# Analysts---122345667223149816
Surprise %---0.00%-0.01%2.31%0.01%1.23%1.94%-0.01%0.00%1.12%0.88%1.00%0.44%0.42%

vTv Therapeutics's average Quarter revenue forecast for Jun 24 based on 0 analysts is -, with a low forecast of -, and a high forecast of -. VTVT's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of $9.00K (Dec 22).

vTv Therapeutics EBITDA Forecast

Dec 24Sep 24Jun 24Dec 22Sep 22Dec 21Sep 21Jun 21Mar 21Dec 20Jun 20Dec 19Sep 19Jun 19Mar 18Mar 17Mar 16Sep 15
# Analysts---122345667223149816
EBITDA---$-6.08M$-5.44M$5.74M$-959.00K$-586.00K$-4.20M$1.22M$-3.12M$-4.10M$-3.20M$-2.26M$-2.06M$-3.61M$-3.77M$-3.66M
Avg Forecast---$2.45M$-150.00K$-300.00K$-780.00K$-600.00K$-2.80M$-1.98M$-5.80M$-753.00K$-1.01M$-2.26M$-2.30M$-3.61M$-5.31M$-5.21M
High Forecast---$2.94M$-150.00K$-300.00K$-780.00K$-600.00K$-2.24M$-1.98M$-4.64M$-753.00K$-1.01M$-1.81M$-1.84M$-2.89M$-4.24M$-4.17M
Low Forecast---$1.96M$-150.00K$-300.00K$-780.00K$-600.00K$-3.36M$-1.98M$-6.96M$-753.00K$-1.01M$-2.71M$-2.76M$-4.33M$-6.37M$-6.25M
Surprise %----2.48%36.24%-19.12%1.23%0.98%1.50%-0.61%0.54%5.45%3.16%1.00%0.89%1.00%0.71%0.70%

2 analysts predict VTVT's average Quarter EBITDA for Sep 22 to be $-150.00K, with a high of $-150.00K and a low of $-150.00K. This is -102.62% lower than vTv Therapeutics's previous annual EBITDA (Dec 21) of $5.74M.

vTv Therapeutics Net Income Forecast

Dec 24Sep 24Jun 24Dec 22Sep 22Dec 21Sep 21Jun 21Mar 21Dec 20Jun 20Dec 19Sep 19Jun 19Mar 18Mar 17Mar 16Sep 15
# Analysts---122345667223149816
Net Income---$-5.89M$-4.26M$8.23M$-1.09M$-608.00K$-4.24M$1.13M$-3.37M$-4.40M$-3.61M$-2.88M$-2.95M$-4.22M$-3.85M$-4.10M
Avg Forecast$-20.49M$-23.05M$-20.49M$2.27M$-11.10M$-16.22M$-16.65M$-17.93M$-2.83M$-14.09M$-4.12M$-24.33M$-28.18M$-2.88M$-3.30M$-4.22M$-5.42M$-5.84M
High Forecast$-20.49M$-23.05M$-20.49M$2.73M$-11.10M$-16.22M$-16.65M$-17.93M$-2.26M$-14.09M$-3.29M$-24.33M$-28.18M$-2.31M$-2.64M$-3.38M$-4.33M$-4.67M
Low Forecast$-20.49M$-23.05M$-20.49M$1.82M$-11.10M$-16.22M$-16.65M$-17.93M$-3.39M$-14.09M$-4.94M$-24.33M$-28.18M$-3.46M$-3.96M$-5.06M$-6.50M$-7.01M
Surprise %----2.59%0.38%-0.51%0.07%0.03%1.50%-0.08%0.82%0.18%0.13%1.00%0.89%1.00%0.71%0.70%

vTv Therapeutics's average Quarter net income forecast for Sep 22 is $-11.10M, with a range of $-11.10M to $-11.10M. VTVT's average Quarter net income forecast represents a -234.86% decrease compared to the company's last Quarter net income of $8.23M (Dec 21).

vTv Therapeutics SG&A Forecast

Dec 24Sep 24Jun 24Dec 22Sep 22Dec 21Sep 21Jun 21Mar 21Dec 20Jun 20Dec 19Sep 19Jun 19Mar 18Mar 17Mar 16Sep 15
# Analysts---122345667223149816
SG&A---$2.39M$2.63M$-6.61M$2.22M$2.24M$2.16M$2.04M$1.70M$1.99M$1.77M$2.39M$2.25M$2.82M$2.58M$2.42M
Avg Forecast---$8.85M$717.36K$1.43M$3.73M$2.87M$2.30M$9.47M$29.51K$3.60M$4.84M$4.66M$6.71M$86.08K$2.47M$911.25K
High Forecast---$10.62M$717.36K$1.43M$3.73M$2.87M$2.30M$9.47M$35.41K$3.60M$4.84M$4.66M$8.05M$103.30K$2.96M$1.09M
Low Forecast---$7.08M$717.36K$1.43M$3.73M$2.87M$2.30M$9.47M$23.61K$3.60M$4.84M$4.66M$5.37M$68.87K$1.97M$728.99K
Surprise %---0.27%3.67%-4.61%0.60%0.78%0.94%0.21%57.43%0.55%0.37%0.51%0.34%32.81%1.05%2.65%

vTv Therapeutics's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to VTVT last annual SG&A of $2.39M (Dec 22).

vTv Therapeutics EPS Forecast

Dec 24Sep 24Jun 24Dec 22Sep 22Dec 21Sep 21Jun 21Mar 21Dec 20Jun 20Dec 19Sep 19Jun 19Mar 18Mar 17Mar 16Sep 15
# Analysts---122345667223149816
EPS---$-0.07$-0.05$0.12$-0.02$-0.01$-0.08$0.02$-0.07$-0.13$-0.13$-0.10$-0.30$-0.44$-0.42$-0.49
Avg Forecast$-3.20$-3.60$-3.20$-2.53$-1.73$-2.53$-2.60$-2.80$-2.40$-2.20$-3.80$-3.80$-4.40$-4.20$-0.38$-0.44$-1.35$-1.67
High Forecast$-3.20$-3.60$-3.20$-2.53$-1.73$-2.53$-2.60$-2.80$-2.40$-2.20$-3.80$-3.80$-4.40$-4.20$-0.30$-0.35$-1.08$-1.33
Low Forecast$-3.20$-3.60$-3.20$-2.53$-1.73$-2.53$-2.60$-2.80$-2.40$-2.20$-3.80$-3.80$-4.40$-4.20$-0.46$-0.53$-1.62$-2.00
Surprise %---0.03%0.03%-0.05%0.01%0.00%0.03%-0.01%0.02%0.03%0.03%0.02%0.79%1.00%0.31%0.29%

According to 2 Wall Street analysts, vTv Therapeutics's projected average Quarter EPS for Sep 22 is $-1.73, with a low estimate of $-1.73 and a high estimate of $-1.73. This represents a -1544.44% decrease compared to VTVT previous annual EPS of $0.12 (Dec 21).

vTv Therapeutics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
ELEVElevation Oncology$0.52$9.001630.77%Buy
KRONKronos Bio$0.95$7.63703.16%Buy
GOVXGeoVax Labs$1.79$8.00346.93%Buy
IMMXImmix Biopharma$1.58$7.00343.04%Buy
ERASErasca$2.87$7.00143.90%Buy
PYXSPyxis Oncology$3.80$9.00136.84%Buy
CCCCC4 Therapeutics$6.45$13.50109.30%Buy
EWTXEdgewise Therapeutics$34.48$45.0030.51%Buy
ZURAZura Bio$4.37$5.0014.42%Buy
EFTReFFECTOR Therapeutics-$5.50-Buy
VTVTvTv Therapeutics$14.00$5.00-64.29%Buy

VTVT Forecast FAQ


Yes, according to 1 Wall Street analysts, vTv Therapeutics (VTVT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of VTVT's total ratings.

VTVT's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-64.034M (high $-64.034M, low $-64.034M), average SG&A $0 (high $0, low $0), and average EPS is $-10 (high $-10, low $-10).

Based on vTv Therapeutics's last annual report (Dec 2022), the company's revenue was $2.02M, which missed the average analysts forecast of $3.34M by -39.50%. Apple's EBITDA was $-24.858M, missing the average prediction of $2.3M by -1178.99%. The company's net income was $-25.073M, beating the average estimation of $-8.825M by 184.11%. Apple's SG&A was $12.2M, beating the average forecast of $9.57M by 27.48%. Lastly, the company's EPS was $-0.53, missing the average prediction of $-4.267 by -87.58%. In terms of the last quarterly report (Dec 2022), vTv Therapeutics's revenue was $9K, missing the average analysts' forecast of $3.09M by -99.71%. The company's EBITDA was $-6.084M, missing the average prediction of $2.45M by -347.94%. vTv Therapeutics's net income was $-5.89M, missing the average estimation of $2.27M by -359.02%. The company's SG&A was $2.39M, missing the average forecast of $8.85M by -73.03%. Lastly, the company's EPS was $-0.0723, missing the average prediction of $-2.533 by -97.15%